A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
Safety and Effectiveness of Pradaxa Oral Pellet Formulation for Treatment of Acute Venous Thromboembolic Events (VTE) and/or for Risk Reduction of Recurrence of VTE in Pediatric Patients Aged 3 Months to Less Than 12 Years in a Real World Setting: a Prospective Non-interventional Study Conducted in the United States
Sponsor: Boehringer Ingelheim
Terminated
Low study enrolment.
Other terminated trials from Boehringer Ingelheim
Other Venous Thromboembolism trials with similar outcome
A observational or N/A phase clinical study on Venous Thromboembolism, this trial is terminated or withdrawn. The trial is conducted by Boehringer Ingelheim and has accumulated 16 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
16 versions recorded-
Oct 2025 — Present [monthly]
Terminated
Status: Completed → Terminated
-
Sep 2025 — Oct 2025 [monthly]
Completed
-
Jun 2025 — Sep 2025 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
▶ Show 11 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
-
Jan 2024 — May 2024 [monthly]
Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Not Yet Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Children's Hospital Acquired Thrombosis consortium
For direct contact, visit the study record on ClinicalTrials.gov .